Sakura Bio

About

Headcount over time

Offices

Q&A

What is Sakura Bio's primary focus?

Sakura Bio focuses on developing an off-the-shelf, naïve PBMC-derived allogeneic T-cell therapy to combat cancer, specifically acute myeloid leukemia.

What is Sakura Bio's lead product?

Sakura Bio's lead product is Super Activated Killer T-cell (SAK-T), a unique T-cell population designed for superior anti-tumor cytotoxic activity without toxicity to healthy tissue.

What is the safety profile of SAK-T cells compared to other T-cell products?

SAK-T cells have a high safety profile, with no graft-versus-host disease, distinguishing them from other T-cell-based products like CAR-T.

What is the first-in-human indication for SAK therapy?

Due to SAK-T's killing properties of leukemic cells, Sakura Bio has chosen acute myeloid leukemia as its first-in-human indication for SAK therapy.

When was Sakura Bio founded?

Sakura Bio was founded in October 2022.

How many employees does Sakura Bio currently have?

Sakura Bio has 1-10 employees.

What is Sakura Bio's current funding stage?

Sakura Bio is currently in the Pre-Seed funding stage.

What is the total amount of funding raised by Sakura Bio?

Sakura Bio has raised a total of $1,700,000.

When did Sakura Bio complete its last funding round and who were the lead investors?

In May 2025, Sakura Bio completed a funding round with.

Team · 9

Dikla Berko-Ashur

Founder · Co-founder & CEO

Amnon Peled

Founder · Co-founder & CTO

Tony Peled

CDO

Inbal Mishalian

Head of Preclinical

Anthony Walker, PhD

Key consultor

Dorit Aschengrau

Scientist

Ori Choshen

Board of Directors

Dr. Lior Carmon

Board of Directors

Dr. Ruth Ben Yakar

Board of Directors

Sectors & technology

Tags